Business Context and Reporting Period
This Form 8-K filing by Imunon, Inc. (IMNN) covers events occurring on July 11, 2025. The report addresses a critical regulatory development regarding the company's continued listing on The Nasdaq Capital Market and corporate governance actions taken at the 2025 Annual Meeting of Stockholders.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, or debt levels. However, it references specific financial thresholds required for listing compliance:
- Minimum Bid Price Requirement: $1.00 per share (not met for 30 consecutive business days prior to November 26, 2024).
- Minimum Stockholders' Equity Requirement: $5,000,000 (not met as of May 19, 2025).
Material Changes and Events
Nasdaq Delisting Appeal Outcome
On July 11, 2025, the Nasdaq Hearing Panel granted Imunon an exception to avoid immediate delisting. The company had previously received a delisting determination on May 28, 2025, due to failure to meet the Minimum Bid Price Requirement and the Minimum Stockholders' Equity Requirement. The company was ineligible for a standard 180-day extension because it failed to meet the initial listing equity requirement. The granted exception provides a tailored timeframe for the company to regain compliance with both requirements.
Stock Incentive Plan Amendment
At the Annual Meeting held on July 11, 2025, stockholders approved an amendment to the 2018 Stock Incentive Plan. The amendment increases the aggregate number of shares available for issuance by 2,000,000, raising the total limit to 3,970,000 shares.
Guidance, Outlook, and Risks
Management notes that there is no assurance the company will regain compliance with Nasdaq listing rules or successfully implement a reverse stock split if pursued. The filing highlights significant risks associated with potential delisting, including:
- Reduced liquidity and difficulty in buying or selling shares.
- Potential material decline in stock price.
- Impaired ability to raise capital.
- Triggering of defaults or penalties under existing agreements.
The company is required to provide prompt notification of any significant events that may call into question its ability to satisfy the terms of the granted exception.
Investor Verification Checklist
- Verify the specific timeline and conditions attached to the Nasdaq Hearing Panel's granted exception.
- Monitor the company's stock price to determine if it can sustain the $1.00 minimum bid price requirement.
- Review upcoming financial statements to assess progress toward the $5,000,000 stockholders' equity requirement.
- Check for any announcements regarding a potential reverse stock split.
- Review the amended 2018 Stock Incentive Plan (Exhibit 10.1) for details on the new share limit and award terms.